

CONCLUSIONES

Fruquintinib se asoció con menores costes de manejo de los Eventos Adversos en pacientes con CCRm tratados en fase avanzada en España

MÉTODO

Se elaboró un análisis de costes para estimar el impacto económico asociado al manejo del paciente durante el curso de los EA relacionados con las terapias de tercera línea o posteriores



Fernández A, González Astorga B, Rodríguez N, Safont MJ, Castro Albarran P, Mareque M, Oyagüez I

A Cost Analysis of Adverse Event Management of Systemic Therapies for Metastatic Colorectal Cancer on Patients with at Least Two Previous Lines of Treatment in Spain

ClinicoEconomics and Outcomes Research

Dovepress
Taylor & Francis Group

Open Access Full Text Article

ORIGINAL RESEARCH

A Cost Analysis of Adverse Event Management of Systemic Therapies for Metastatic Colorectal Cancer on Patients with at Least Two Previous Lines of Treatment in Spain

Ana Fernández^{1,*}, Beatriz González Astorga^{2,*}, Nuria Rodríguez^{3,*}, María José Safont^{4,*}, Paula Castro Albarrán⁵, María Mareque⁵, Itziar Oyagüez⁵

¹Medical Oncology Department, Ourense University Hospital Complex, Ourense, Spain; ²Medical Oncology Department, San Cecilio University Hospital, Granada, Spain; ³Medical Oncology Department, La Paz University Hospital, Madrid, Spain; ⁴Medical Oncology Department, General Hospital Consortium, University of Valencia, Valencia, Spain; ⁵Health Economics & Market Access Department, PharmacoEconomics & Outcomes Research Iberia (PORIB), Madrid, Spain